Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(02): 138-140
DOI: 10.4103/2278-330X.130468
Case Report

Role of Crizotinib in previously treated non-small-cell lung cancer

Sunil Kumar Gupta
Department of Medical Oncology, Senior Consultant and Chief of Head and Neck Medical Services, Rajiv Gandhi Cancer Institute and Research Centre, Sector - V, Rohini, New Delhi, India
› Author Affiliations Source of Support: Nill.
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • A A Parikh P, Puri T. Personalized medicine: Lung Cancer leads the way. Indian J Cancer 2013;50:77-9.
  • 1 Globocan 2008 data. Available from: http://globocan.iarc.fr/factsheet.asp [Last accessed on 2012 Sep 26].
  • 2 Konopa K, Jassem J. The role of pemetrexed combined with targeted agents for non-small cell lung cancer. Curr Drug Targets 2010;11:2-11.
  • 3 Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: Potential role of cetuximab. Biologics 2009;3:215-24.
  • 4 American cancer society. Detailed guide: Lung cancer - non-small cell. Non-small cell lung cancer survival rates by stage. Available from: http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/index [Last accessed on 2012 Mar 22].
  • 5 Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
  • 6 Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.: North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
  • 7 Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al.: West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
  • 8 Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009,361:947-57.
  • 9 Gandhi L, Jänne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target. Clin Cancer Res 2012;18:3737-42.
  • 10 Shaw AT, Engelmann JA. ALK in lung cancer: Past, present, and future. J Clin Oncol 2013;31:1105-11.
  • 11 New 12 National comprehensive cancer network clinical practice guidelines in oncology: Non Small cell lung cancer. Version. 2.2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Last accessed on 2013 Mar 12].
  • 12 Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.